The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In patients with high-risk multiple myeloma, maintenance therapy with belantamab, pomalidomide, and dexamethasone (BPD) demonstrated encouraging activity and a manageable safety profile, according
Daratumumab raises early infection risks in patients treated with multiple myeloma, according to an oral abstract presented on September 17, 2025, at the
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Reem Karmali, MD, an associate professor
Patients with polycythemia vera (PV) who received GLP-1a therapy had markedly better outcomes than patients who did not, according to a retrospective study
Achievement of early measurable residual disease (MRD) negativity under assessment with next-generation sequencing (NGS) is associated with durable remissions in patients with newly
After the lights go down on SOHO 2025, John DiPersio, MD, PhD, will step into his role as the 2025-2026 SOHO president. Looking
“I think we’re poised to develop experimental models through genome editing and other approaches,” Dr. Mullighan said. “We’re also using our experience from
Guillermo Garcia-Manero, MD, and Hagop Kantarjian, MD, discuss the phase 3 VERONA trial at SOHO 2025. Visit the SOHO 2025 meeting news page
Today, Jennifer R. Brown, MD, PhD, will be honored with the Michael J. Keating Outstanding Achievement Award, which recognizes a clinician’s significant research contributions
One of SOHO’s most dedicated and longest-standing members, Dr. Lonial chairs the Education Committee, serves as Treasurer, and is editor in chief of
